[5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides -> Monitor Keywords

Site News |

Monitor Keywords |

Monitor Archive |

Organizer |

Account Info |

11/27/08 - USPTO Class 514 | 1 views | #20080293668 | Prev - Next | About this Page

[5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides

Title: [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20080293668, [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides.

1. A compound of the structure: wherein X is O, S, CH2, CHF, or CF2; Y is O, S, CH2, CHF, CF2; Z is independently O, S or Se; R1 is independently H or F; R2 is independently H, OH, C1 to C6 alkyl, or C(O)(C1 to C6 alkyl); R3 is H, C(O)(C1-C6 alkyl); alkyl, or mono-, di- or triphosphate; and R4 is independently H, F, Cl, Br, I, OH, —O(C1-C6alkyl), —SH, —S(C1-C6alkyl); or —C1-C6alkyl.

2. The compound of claim 1, wherein Y is O or S; Z is O; R1 is H; R2 is H; and R3 is H.

3. The compound of claim 1, wherein X is O or S; Y is O; Z is 0; R1 is H; R2 is H; R3 is H, and R4 is independently H or Fl.

4. The compound of claim 1 in the form of a racemic mixture.

5. The compound of claim 1 in the form of a β-D-enantiomer.

6. The compound of claim 1 in the form of a β-L-enantiomer.

7. The compound of claim 1 in enantiomerically enriched form.

8. The compound of claim 1 selected from the group consisting of the racemic mixture, β-D- or β-L-enantiomer of 2-hydroxymethyl-5-(N-5′-carboxamidouracil-1′-yl)-1,3-oxathiolane; 2-hydroxymethyl-4-(N-5′-carboxamidouracil-1′-yl)-1,3-dioxolane; 2-hydroxymethyl-4-(N-5′-fluorocytosin-1′-yl)-1,3-dithiolan; 2-hydroxymethyl-4-(N-5′-carboxamidouracil-1′-yl)-1,3-dithiolan; 2-hydroxymethyl-4-(N-5′-fluorocytosin-1′-yl)-1,3-oxathiolane; 2-hydroxymethyl-4-(N-5′-carboxamidouracil-1′-yl)-1,3-oxathiolane; 2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-5-carboxamidocytidine; 2′,3′-dideoxy-5-fluorocytidine; 2′,3′-dideoxy-5-carboxamidocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′,5-difluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′-fluoro-5-carboxamidocytidine, 2′,3′-dideoxy-2′,3′-didehydro-3′,5-difluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-3′-fluoro-5-carboxamidocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′,3′,5-trifluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′,3′-difluoro-5-carboxamidocytidine; 2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-5-carboxamidocytidine; 2′,3′-dideoxy-5-fluorocytidine; 2′,3′-dideoxy-5-carboxamidocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′,5-difluorocytidine; 2′,3′-dideoxy-2′,3′-didehydro-2′-fluoro-5-carboxamidocytidine; 2′,3′-dideoxy-2′,3′-didehydro-3′,5-difluorouridine; 2′,3′-dideoxy-2′,3′-didehydro-3′-fluoro-5-carboxamidouridine; 2′,3′-dideoxy-2′,3′-didehydro-2′,3′,5-trifluorouridine; and 2′,3′-dideoxy-2′,3′-didehydro-2′,3′-difluoro-5-carboxamidouridine.

9. The compound of claim 1 selected from the group consisting of the racemic mixture, the β-L-enantiomer and the β-D-enantiomer of 5-carboxylic acid amide-2′,3′-dideoxy-3′-thiacytidine.

10. A composition comprising an effective HIV or HBV treatment amount of a compound of claim 1 in combination with a compound selected from the group consisting of the (−)-enantiomer of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC); the (−)-enantiomer of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC); carbovir, acyclovir, interferon, AZT, DDI, DDC, L-(−)-FMAU, and D4T.

11. A pharmaceutical composition comprising an effective amount to treat HIV or HBV infection in humans of a compound of claim 1 in the racemic or enantiomerically enriched form, or its physiologically acceptable salt, in a pharmaceutically acceptable carrier.

12. A method for treating HIV infection in humans comprising administering an effective amount of a compound of claim 1 or its physiologically acceptable derivative or physiologically acceptable salt, in a pharmaceutically acceptable carrier.

13. A method for treating HBV infection in humans comprising administering an effective amount of a compound of claim 1 or its physiologically acceptable derivative or physiologically acceptable salt, in a pharmaceutically acceptable carrier.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides patent application.
###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides or other areas of interest.
###

Previous Patent Application:
Lipid analogs for combating tumors
Next Patent Application:
Composition containing beta-glucan, method of producing the same and foods, drinks or skin moisturizers containing the composition
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides patent info.
IP-related news and info

Results in 0.10209 seconds

Other interesting Feshpatents.com categories:
Novartis , Pfizer , Philips , Polaroid , Procter & Gamble , 174

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO